(Q36655168)

15 August 2017

1 reference

title

Emerging treatments for depression (English)

1 reference

15 August 2017

Paul E Holtzheimer

1

1 reference

15 August 2017

Charles B Nemeroff

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

17

1 reference

15 August 2017

page(s)

2323-2339

1 reference

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Diagnosis and definition of treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

The empirical status of cognitive-behavioral therapy: A review of meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

The current state of cognitive therapy: a 40-year retrospective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Neuroimaging and the functional neuroanatomy of psychotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Convulsive therapy: a review of the first 55 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Comparison of clinical efficacy and side effects for bitemporal and bifrontal electrode placement in electroconvulsive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

ECT of major depressed patients in relation to biological and clinical variables: a brief overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Transdermal selegiline: targeted effects on monoamine oxidases in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Dopamine, depression and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Central monoamines and their role in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

"Broad spectrum" antidepressants: is more better for the treatment of depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

The Mechanism of Action of Novel Antipsychotic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

The role of corticotropin-releasing factor in depression and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

The CRF peptide family and their receptors: yet more partners discovered

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Treatment of depression with antiglucocorticoid drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Cortisol activity and cognitive changes in psychotic major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Rapid reversal of psychotic depression using mifepristone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

An open label trial of C-1073 (mifepristone) for psychotic major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Role of corticotropin-releasing factor and substance P in pressor responses of nuclei controlling emotion and stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Distribution and origins of substance P-immunoreactive projections to the paraventricular and supraoptic nuclei: partial overlap with ascending catecholaminergic projections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Synaptic inputs of tachykinin-containing nerve terminals to target tyrosine-hydroxylase-, beta-endorphin- and neuropeptide Y-producing neurons of the arcuate nucleus. Double pre-embedding immunocytochemical study in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Interactions and coexistence of neuropeptides and serotonin in spinal autonomic systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Central tachykinins: mediators of defence reaction and stress reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Substance P serum levels are increased in major depression: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Glutamate and depression: clinical and preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Stress and hippocampal plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Amantadine as augmentation therapy in the management of treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Enhancement of antidepressant potency by a potentiator of AMPA receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Antidepressant effect of ketamine during ECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

An open-label trial of riluzole in patients with treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Omega-3 fatty acids and mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Is low dietary intake of omega-3 fatty acids associated with depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Omega-3 Eicosapentaenoic Acid in Bipolar Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Melatonin in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Melatonin treatment of winter depression: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Melatonin for the Treatment of Sleep Disturbances in Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Vagus-nerve stimulation for the treatment of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Vagus nerve stimulation, side effects, and long-term safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Vagus nerve stimulation (VNS): utility in neuropsychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Vagus nerve stimulation is associated with mood improvements in epilepsy patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Vagus nerve stimulation in chronic treatment-resistant depression: preliminary findings of an open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

A review of functional neuroimaging studies of vagus nerve stimulation (VNS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Serotonin receptor subtypes involved in vagus nerve stimulation-induced phrenic long-term facilitation in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Recordings from the rat locus coeruleus during acute vagal nerve stimulation in the anaesthetised rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Locus coeruleus activation by colon distention: role of corticotropin-releasing factor and excitatory amino acids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

The effects of peripheral vagal nerve stimulation at a memory-modulating intensity on norepinephrine output in the basolateral amygdala

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Correlation between GABA(A) receptor density and vagus nerve stimulation in individuals with drug-resistant partial epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Vagus nerve stimulation (VNS) is effective in a rat model of antidepressant action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Transcranial magnetic stimulation: neurophysiological applications and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Repetitive transcranial magnetic stimulation for the treatment of depression. Systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

A double-blind sham controlled study of right prefrontal repetitive transcranial magnetic stimulation (rTMS): therapeutic and cognitive effect in medication free unipolar depression during 4 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Efficacy of repetitive transcranial magnetic stimulation (rTMS) in the treatment of affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Transcranial magnetic stimulation in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Transcranial magnetic stimulation as a therapeutic tool in psychiatry: what do we know about the neurobiological mechanisms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Effects of acute repetitive transcranial magnetic stimulation on dopamine release in the rat dorsolateral striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Endogenous dopamine release induced by repetitive transcranial magnetic stimulation over the primary motor cortex: an [11C]raclopride positron emission tomography study in anesthetized macaque monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Transcranial magnetic stimulation induces increases in extracellular levels of dopamine and glutamate in the nucleus accumbens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Repetitive transcranial magnetic stimulation increases the release of dopamine in the mesolimbic and mesostriatal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Chronic repetitive transcranial magnetic stimulation alters beta-adrenergic and 5-HT2 receptor characteristics in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Opposite effects of high and low frequency rTMS on regional brain activity in depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Correlation of cerebral blood flow and treatment effects of repetitive transcranial magnetic stimulation in depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Unilateral left prefrontal transcranial magnetic stimulation (TMS) produces intensity-dependent bilateral effects as measured by interleaved BOLD fMRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Intensity-dependent regional cerebral blood flow during 1-Hz repetitive transcranial magnetic stimulation (rTMS) in healthy volunteers studied with h215o positron emission tomography: II. effects of prefrontal cortex rTMS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Low frequency rTMS as an add-on antidepressive strategy: heterogeneous impact on 99mTc-HMPAO and 18 F-FDG uptake as measured simultaneously with the double isotope SPECT technique. Pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Magnetic seizure therapy improves mood in refractory major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Anesthetic considerations for magnetic seizure therapy: a novel therapy for severe depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Deep brain stimulation of the subthalamic nucleus for Parkinson's disease: a therapy approaching evidence-based standards.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Deep brain stimulation for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Electrical stimulation of the anterior limbs of the internal capsules in patients with severe obsessive-compulsive disorder: anecdotal reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Deep brain stimulation for treatment of refractory depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Uncovering the mechanism(s) of action of deep brain stimulation: activation, inhibition, or both.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Predictors of response to amine-specific antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Major depressive subtypes and treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Atypical depression, atypical temperament and a differential antidepressant response to fluoxetine and nortriptyline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Shorter duration of depressive episode may predict response to repetitive transcranial magnetic stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Biological and clinical predictors of response in recurrent depression: a preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

All-night EEG spectral analysis as a tool for the prediction of clinical response to antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Cingulate function in depression: a potential predictor of treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Limbic-frontal circuitry in major depression: a path modeling metanalysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

The DST as a predictor of outcome in depression: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

Immunoreactive substance P and serotonin present in the same dense-core vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2323

10.1517/14656566.7.17.2323

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference